Pharmaceutical industry money can't replace NIH funding

From STAT News

By Jerry Avorn, MD

SUMMARY: In this STAT News First Opinion essay, Dr. Avorn argues that private pharmaceutical investment cannot substitute for federal NIH funding. He opens with a historical account: around 1990, a Harvard researcher investigating a little-known peptide with potential to slow gastric emptying and reduce hunger — what would later become the basis for the GLP-1 drug class — sought pharmaceutical-company support because federal funding was unavailable. The drugmaker that provided support required secrecy and ultimately failed to follow up on the enormous therapeutic and commercial potential of the compound, delaying by years the development of what is now a blockbuster drug class. Avorn uses this story to illustrate a structural problem: when pharmaceutical companies fund early-stage research, commercial logic — not scientific or public health logic — determines what gets pursued, protected, and published. NIH funding, by contrast, supports open science, knowledge sharing, and the unpredictable long-range basic research that underlies the most transformative medical advances.

BACKGROUND: A Harvard researcher in approximately 1990 pursued early research on a peptide — the precursor to the GLP-1 drug class — with pharmaceutical-company support because NIH funding was unavailable.

KEY FINDINGS: The drugmaker required secrecy and failed to follow up on the compound's enormous potential, losing billions in potential revenue and delaying a transformative drug class. The privatization of medical research cannot replace what the NIH has provided.

IMPLICATIONS: Federal investment in open basic science is irreplaceable. Private pharmaceutical funding introduces commercial logic that distorts scientific priorities and delays or suppresses findings in the public interest.